180 related articles for article (PubMed ID: 21196588)
1. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series.
Record JL; Beukelman T; Cron RQ
J Rheumatol; 2011 Jan; 38(1):180-1. PubMed ID: 21196588
[No Abstract] [Full Text] [Related]
2. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA).
Ohlsson V; Baildam E; Foster H; Jandial S; Pain C; Strike H; Ramanan AV
Rheumatology (Oxford); 2008 Apr; 47(4):555-6. PubMed ID: 18321945
[No Abstract] [Full Text] [Related]
3. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
Nigrovic PA; Mannion M; Prince FH; Zeft A; Rabinovich CE; van Rossum MA; Cortis E; Pardeo M; Miettunen PM; Janow G; Birmingham J; Eggebeen A; Janssen E; Shulman AI; Son MB; Hong S; Jones K; Ilowite NT; Cron RQ; Higgins GC
Arthritis Rheum; 2011 Feb; 63(2):545-55. PubMed ID: 21280009
[TBL] [Abstract][Full Text] [Related]
4. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
5. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease.
Woo P
Ann Rheum Dis; 2008 Mar; 67(3):281-2. PubMed ID: 18292104
[No Abstract] [Full Text] [Related]
6. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
Swart JF; Barug D; Möhlmann M; Wulffraat NM
Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
[TBL] [Abstract][Full Text] [Related]
7. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report.
Angeles-Han S; Flynn T; Lehman T
J Rheumatol; 2008 Sep; 35(9):1897-8. PubMed ID: 18785302
[No Abstract] [Full Text] [Related]
8. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
Verbsky JW; White AJ
J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
10. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al.
Elhai M; Deslandre CJ; Kahan A
Arthritis Care Res (Hoboken); 2011 Feb; 63(2):307-8; author reply 308. PubMed ID: 20890986
[No Abstract] [Full Text] [Related]
11. [New treatments for idiopathic juvenile arthritis].
Bader-Meunier B; Quartier P
Arch Pediatr; 2009 Dec; 16(12):1607-11. PubMed ID: 19896351
[TBL] [Abstract][Full Text] [Related]
12. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis.
Zulian F; Balzarin M; Falcini F; Martini G; Alessio M; Cimaz R; Cimino L; Zannin ME
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):821-5. PubMed ID: 20191477
[TBL] [Abstract][Full Text] [Related]
13. Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis.
Mirkinson LJ; Nagle D; Kadom N; Jones OY
J Clin Rheumatol; 2006 Apr; 12(2):83-6. PubMed ID: 16601542
[TBL] [Abstract][Full Text] [Related]
14. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Horneff G; Huppertz HI; Job-Deslandre C; Loy A; Minden K; Punaro M; Nunez AF; Sigal LH; Block AJ; Nys M; Martini A; Giannini EH;
Arthritis Rheum; 2010 Jun; 62(6):1792-802. PubMed ID: 20191582
[TBL] [Abstract][Full Text] [Related]
16. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.
Narváez J; Díaz-Torné C; Juanola X; Geli C; Llobet JM; Nolla JM; Díaz-López C
Ann Rheum Dis; 2009 Apr; 68(4):607-8. PubMed ID: 19286909
[No Abstract] [Full Text] [Related]
17. Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis.
Remesal A; DE Inocencio J; Merino R; Garcia-Consuegra J
J Rheumatol; 2010 Sep; 37(9):1970-1. PubMed ID: 20810527
[No Abstract] [Full Text] [Related]
18. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
[TBL] [Abstract][Full Text] [Related]
19. A case of macrophage activation syndrome successfully treated with anakinra.
Kelly A; Ramanan AV
Nat Clin Pract Rheumatol; 2008 Nov; 4(11):615-20. PubMed ID: 18825135
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases.
Botsios C; Sfriso P; Ostuni PA; Todesco S; Punzi L
Rheumatology (Oxford); 2007 Jun; 46(6):1042-3. PubMed ID: 17449489
[No Abstract] [Full Text] [Related]
[Next] [New Search]
